Antibody treatment with anti-S100A8/9 has been proven effective in mouse models of colitis, acute myocardial infarction, and pancreatitis, which reveals the effect of anti-S100A8/9 antibody treatment on inflammatory diseases [53,54,55]. Here, S100A8 is linked to myocardial infarction.